Does rhinitis pharmacotherapy improve control of comorbid asthma?
| dc.contributor.author | Şenel F.Ç. | |
| dc.contributor.author | Yorgancioğlu A. | |
| dc.contributor.author | Cruz A.A. | |
| dc.date.accessioned | 2024-07-22T08:07:08Z | |
| dc.date.available | 2024-07-22T08:07:08Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Asthma is a disorder usually characterised by chronic inflammation of the airway mucosa of the bronchi and also the more distal airways, featuring a varying (and often remediable) degree of airflow limitation, hyperreactivity of the bronchi and periodic flare-ups, in which respiratory difficulties, such as wheeze, cough with sputum, shortness of breath and a tight chest, are the most common symptoms. AR, which may occur together with conjunctivitis, affects the supralaryngeal portion of the airways and is triggered by the nasal epithelium coming into contact with allergens, thus provoking an inflammatory response initiated by specific IgE. Patients complain of nasal discharge, pruritus, sneeze and blockage of the nose. There is a similar inflammatory pattern in both regions of the airway, if AR or asthma is chronic or when allergens are deliberately presented to the airway mucosa in a provocation test. In both conditions, there are indications of a systemic inflammatory response that may lead to eosinophilic inflammation of the entire airways. Asthma and AR are frequently found together, and AR is a strong predictor for asthma. The fact that asthma and AR can both be treated in similar fashion is also suggestive of a close similarity between the two conditions. Guidelines for management pay attention to this connection and advise assessing patients presenting with asthma for AR and vice versa. Pharmacotherapy should aim to treat both disorders simultaneously for maximum control and to reduce the number of agents needed for treatment. It is plausible that treatment guidelines may eventually suggest a goal of managing the entire respiratory system at once. Such a development would pave the way for a fully inclusive view of personalised holistic management of both the upper and lower airway. © Springer Nature Switzerland AG 2021. | |
| dc.identifier.DOI-ID | 10.1007/978-3-030-50899-9_41 | |
| dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13851 | |
| dc.language.iso | English | |
| dc.publisher | Springer International Publishing | |
| dc.title | Does rhinitis pharmacotherapy improve control of comorbid asthma? | |
| dc.type | Book chapter |